Thurau Stephan R, Wildner Gerhild
Section of Immunobiology, Department of Ophthalmology, Ludwig-Maximilians-University, Mathildenstr. 8, 80336 Munich, Germany.
Autoimmun Rev. 2003 Jun;2(4):171-6. doi: 10.1016/s1568-9972(03)00011-9.
Autoimmune uveitis is a sight threatening disease, which is conventionally treated with immunosuppressive medication. New treatment strategies include immunological approaches and aim at antigen specificity like oral tolerance. A peptide from the sequence of certain HLA-class I molecules plays a central role in the pathogenesis. When T cells recognize the HLA-peptide and are activated they are enabled to pass the blood-retina barrier. In the eye they recognize a cross-reactive organ-specific peptide and cause inflammation, which presents as uveitis. Here, we used the HLA-peptide as oral tolerogen to treat uveitis patients in an open study. All patients showed a positive therapeutic response and could reduce their long-lasting conventional immunosuppressive treatment. We did not observe any side effects. Moreover, side effects from conventional therapy could be reduced significantly.
自身免疫性葡萄膜炎是一种威胁视力的疾病，传统上用免疫抑制药物治疗。新的治疗策略包括免疫方法，旨在实现抗原特异性，如口服耐受。来自某些HLA - I类分子序列的一种肽在发病机制中起核心作用。当T细胞识别HLA肽并被激活时，它们能够穿过血视网膜屏障。在眼中，它们识别一种交叉反应性器官特异性肽并引发炎症，表现为葡萄膜炎。在此，我们在一项开放性研究中使用HLA肽作为口服耐受原治疗葡萄膜炎患者。所有患者均显示出积极的治疗反应，并且能够减少长期的传统免疫抑制治疗。我们未观察到任何副作用。此外，传统疗法的副作用可显著减少。
